March 19, 2021
Nippon Shinyaku said on March 18 that it has obtained exclusive rights in Japan to develop and commercialize Italian drug maker Menarini Group’s tagraxofusp, a treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare aggressive form of blood cancer...read more